BPC-157 Dosage Protocol: Research Ranges, Cycle Length, and Timing

Disclaimer: This guide is for research and educational purposes only. It is not medical advice. BPC-157 is a research compound not approved by the FDA for human use. Consult a licensed healthcare professional before using any injectable compound.

BPC-157 (Body Protection Compound-157) is one of the most studied peptides in preclinical research. A partial sequence of a gastric peptide found naturally in human gastric juice, it has been the subject of extensive animal studies examining its effects on tissue healing, inflammation, and gut function.

This guide covers the dosage ranges most commonly referenced in research contexts, how to structure a protocol, and the practical details of working with BPC-157 in a research setting.

---

What the Research Shows

The majority of BPC-157 studies have been conducted in rodent models. Key findings from the published literature include:

• Tendon and ligament healing: Multiple studies have observed accelerated healing of surgically severed tendons in rats, with improved collagen organization and tensile strength.
• Gut mucosal repair: As a gastric peptide derivative, BPC-157 has shown protective and regenerative effects on intestinal epithelium in inflammatory models.
• Bone and muscle tissue: Some studies report accelerated repair in muscle crush injury and bone defect models.
• Neurological effects: A smaller body of research suggests effects on dopaminergic and serotonergic systems, though this area is less developed.

Human clinical trials on BPC-157 are limited. Most research conclusions are extrapolated from animal data. This is an important context to keep in mind when evaluating any protocol.

---

Standard Research Dosage Range

The most commonly referenced dosage range in BPC-157 research protocols is 250–500 mcg per day, administered subcutaneously or intramuscularly.

Lower end: 250 mcg/day

• Often used as a starting point in conservative protocols
• More appropriate for researchers with lower body weight or sensitivity to new compounds
• Still within the range showing effects in most animal studies when scaled for body weight

Higher end: 500 mcg/day

• The more commonly referenced dose in community research contexts
• Frequently cited in protocols targeting faster or more significant tissue repair
• Some protocols extend to 600–750 mcg/day, though this is less common and less supported by literature directly

There is no established minimum effective dose or maximum safe dose for humans — these figures are drawn from animal study scaling and community convention, not controlled human trials.

---

Once Daily vs Twice Daily Dosing

Once Daily

A single daily injection is simpler and reduces the number of injection events. Some researchers prefer to take a single 500 mcg dose each morning or evening and maintain that consistency throughout the protocol.

This approach is easier to sustain over a longer cycle and is commonly reported as effective in the research community.

Twice Daily (Split Dosing)

Split dosing — typically 250 mcg in the morning and 250 mcg in the evening — is favored by some researchers on the basis that BPC-157 has a relatively short half-life in the body. By splitting the dose, they aim to maintain more consistent plasma levels throughout the day.

This approach is more demanding in terms of injection frequency but is commonly used in protocols targeting acute injury or more aggressive research timelines.

Which to Choose

Both approaches appear in published protocols. For a first research cycle, once daily dosing is simpler and easier to track. Split dosing can be adopted if the protocol is extended or if the research question specifically benefits from more consistent coverage.

---

Cycle Length

BPC-157 protocols in the research community most commonly run 4 to 12 weeks.

Short cycles (4–6 weeks)

Shorter cycles are often used when the research focus is on a specific acute injury or repair process. Once the period of active healing has concluded, the protocol is typically discontinued.

Longer cycles (8–12 weeks)

Longer protocols are more common in research exploring chronic conditions, gut repair, or systemic protective effects. Some researchers run continuous protocols beyond 12 weeks, though there is little long-term safety data for this approach in humans.

Post-cycle break

Most protocols include a break of equal or greater length to the cycle itself before repeating, both as a precautionary measure and to assess baseline changes before beginning another run.

---

How to Calculate Your Dose

BPC-157 is typically sold as a lyophilized powder in 5 mg vials. The concentration of your solution depends on how much bacteriostatic water you add during reconstitution.

A common reconstitution:

• 5 mg vial + 2 mL bacteriostatic water = 2,500 mcg/mL
• On a U-100 insulin syringe (100 units = 1 mL), each unit = 25 mcg
• A 250 mcg dose = 10 units
• A 500 mcg dose = 20 units

You can also use the PeptideHub calculator — enter your vial size, the amount of bac water used, and your target dose, and it will output the exact number of units to draw.

---

Storage Guidelines

BPC-157 is moderately stable but requires proper storage to maintain potency.

Lyophilized (powder, unreconstituted):

• Room temperature for short-term (days to weeks) if sealed
• Refrigerator (2–8°C) for medium-term (months)
• Freezer (-20°C) for long-term storage (up to 12–24 months)
• Keep away from light and moisture

Reconstituted (in solution):

• Refrigerate at 2–8°C immediately after reconstitution
• Use within 30 days
• Do not freeze reconstituted solution — this can degrade peptide bonds
• Label the vial with the reconstitution date

For a detailed storage guide covering multiple peptide types, see Peptide Storage Guide.

---

Injection Route and Site

BPC-157 is administered either subcutaneously (into fat tissue) or intramuscularly (into muscle). SubQ is the most commonly used route for general systemic protocols. Some researchers use IM or even localized injections near the site of injury being studied, based on animal model precedents where local injection was used.

For full technique guidance, see How to Inject Peptides.

---

FAQ

What is the most commonly referenced BPC-157 dose in research? The 250–500 mcg per day range appears most frequently in both published animal literature (scaled to human equivalent dose) and community research protocols. Most researchers start at 250 mcg once daily and adjust based on their protocol objectives.

How long does a BPC-157 cycle typically last? Most protocols run between 4 and 12 weeks. Shorter cycles of 4–6 weeks are used for acute injury research; longer cycles of 8–12 weeks are more common for chronic or systemic research questions.

Should I inject BPC-157 near the injury site or systemically? Animal studies have used both local and systemic (distal) injections with apparent efficacy. The majority of community research protocols use standard subQ sites (abdomen, thigh) rather than local injection, as this is simpler and less technique-dependent.

Does BPC-157 need to be cycled? Most researchers follow a cycle-and-break structure as a precaution, typically matching the break length to the cycle length. There is no established data on the long-term effects of continuous BPC-157 use in humans.

Can BPC-157 be taken orally instead of injected? Some animal studies have used oral administration of BPC-157, particularly in gut-focused research, with apparent effects — possibly due to its gastric origin. However, oral bioavailability for systemic purposes is considered to be much lower than subcutaneous injection. Most research protocols targeting systemic effects use injectable administration.

---

Next Steps

• Use the PeptideHub calculator to calculate your BPC-157 draw volume.
• Read How to Reconstitute Peptides for step-by-step vial prep.
• See How to Inject Peptides for injection technique.
• Visit the peptide directory to compare BPC-157 with related compounds like TB-500.